Tommy Rampling
Impact in
- Virology top 0.5%
- Poxvirus research and outbreaks
- Infectious Diseases top 0.1%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
Papers in
-
- SARS-CoV-2 and COVID-19 Research 18
- COVID-19 Clinical Research Studies 9
- Viral Infections and Outbreaks Research 8
- SARS-CoV-2 detection and testing 2
- Virology 16
- Poxvirus research and outbreaks 16
- Co-authors
- Catherine Houlihan (12 shared papers)Hannah M. Rickman (1 shared paper)Maryam Shahmanesh (1 shared paper)Eleni Nastouli (1 shared paper)Pietro G. Coen (1 shared paper)Gee Yen Shin (1 shared paper)Adrian V. S. Hill (5 shared papers)Michael Marks (5 shared papers)
- Journals
- The Lancet Infectious Diseases (11 papers)The Lancet (7 papers)Journal of Infection (6 papers)The Journal of Infectious Diseases (4 papers)Open Forum Infectious Diseases (4 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Tommy Rampling
79 papers receiving 10.2k citations
Tommy Rampling's Hit Papers
Peers
Comparison fields: 5 of 144
- Virology 1.5k
- Infectious Diseases 6.1k
- Modeling and Simulation 380
- Health 459
- Public Health, Environmental and Occupational Health 887
Countries citing papers authored by Tommy Rampling
This map shows the geographic impact of Tommy Rampling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tommy Rampling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tommy Rampling more than expected).
Fields of papers citing papers by Tommy Rampling
This network shows the impact of papers produced by Tommy Rampling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tommy Rampling. The network helps show where Tommy Rampling may publish in the future.
Co-authors
The 25 scholars most cited alongside Tommy Rampling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Hit paper breakdown → | 2020 | 3698 |
| 2 | Clinical features and management of human monkeypox: a retrospective observational study in the UK Hit paper breakdown → | 2022 | 971 |
| 3 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Hit paper breakdown → | 2021 | 894 |
| 4 | Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Hit paper breakdown → | 2021 | 505 |
| 5 | Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial Hit paper breakdown → | 2021 | 405 |
| 6 | A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA Hit paper breakdown → | 2015 | 302 |
| 7 | Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study Hit paper breakdown → | 2021 | 294 |
| 8 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 9 | 2020 | 197 | |
| 10 | 2015 | 189 | |
| 11 | 2020 | 185 | |
| 12 | Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021 Hit paper breakdown → | 2021 | 169 |
| 13 | 2020 | 145 | |
| 14 | 2021 | 145 | |
| 15 | 2022 | 138 | |
| 16 | 2022 | 134 | |
| 17 | 2021 | 121 | |
| 18 | 2014 | 117 | |
| 19 | Genomic investigations of unexplained acute hepatitis in children Hit paper breakdown → | 2023 | 95 |
| 20 | 2014 | 93 |
About Tommy Rampling
Tommy Rampling is a scholar working on Infectious Diseases, Virology, Public Health, Environmental and Occupational Health, Parasitology and Oncology, having authored 81 papers that have together received 10.6k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (18 papers), Poxvirus research and outbreaks (16 papers), Malaria Research and Control (14 papers), COVID-19 Clinical Research Studies (9 papers), Viral Infections and Outbreaks Research (8 papers), Mosquito-borne diseases and control (4 papers), SARS-CoV-2 detection and testing (2 papers) and COVID-19 and healthcare impacts (2 papers). The work is most often cited by research in Virology (1.5k citations), Infectious Diseases (6.1k citations), Modeling and Simulation (380 citations), Health (459 citations) and Public Health, Environmental and Occupational Health (887 citations). Tommy Rampling has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Catherine Houlihan, Hannah M. Rickman, Maryam Shahmanesh, Eleni Nastouli, Pietro G. Coen, Gee Yen Shin, Adrian V. S. Hill, Michael Marks, Katie Ewer and Georgina Bowyer. Their work appears in journals such as The Lancet Infectious Diseases, The Lancet, Journal of Infection, The Journal of Infectious Diseases and Open Forum Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.